Tuberculosis is a major global health threat even today, claiming the lives of millions each year, despite the availability of effective treatments for the disease. The emergence of drug resistance and limitations of existing therapies demand the continuous development of new and improved drugs. This new book provides a comprehensive overview of the latest progress in this field, covering state-of-the-art approaches to untangle the complexities of drug resistance.
The book explores diagnosis methods, drug resistance mechanisms, and limitations in existing drugs and proposes strategies such as structural modifications, efflux pathway targeting, and host-directed therapies to overcome resistance. It also looks at artificial intelligence for TB management. Recent advancements in tuberculosis control, vaccine development, and biomarkers are also covered along with visions for the future of TB drug discovery, offering a glimpse into the evolving landscape of combating tuberculosis.
Covers topics, from drug resistance to using AI to enhance treatment methods for TB. Explore TB diagnosis methods, drug resistance mechanisms in TB, and limitations in existing drugs and proposes strategies such as structural modifications, efflux pathway targeting, and host-directed therapies to overcome resistance.
PART I: UNDERSTANDING TUBERCULOSIS (TB) AND ITS CHALLENGES
1.
Tuberculosis Drug Discovery: From Evil to Allies
2. Relationship Between
Covid-19 and Tuberculosis
3. Advancement in the Diagnosis of Tuberculosis
4.
Mechanisms of Drug Resistance in Tuberculosis and Potential Modulation
Strategies PART II: NEW FRONTIERS IN TB DRUG DISCOVERY
5. Outsmarting the
Superbug: A Look at New Targets for Tuberculosis Treatment
6. Deciphering
Antitubercular Drug Pharmacokinetics
7. Structure-Based Drug Design for
Tuberculosis PART III: SUCCESS STORIES AND EMERGING HOPE
8. The Journey of
Bedaquiline: Revolutionizing Tuberculosis Treatment
9. Delamanid and
Pretomanid: From Bench to Bedside
10. Overview of DprE1 Inhibitors and
Development of Macozinone and Other Drugs
11. Unleashing the Power Within:
Host Directed Therapies Revolutionizing Tuberculosis Treatment PART IV: TOOLS
AND TECHNOLOGIES FOR A TB-FREE FUTURE
12. Artificial Intelligence in
Tuberculosis Management
13. Novel Drug Delivery Systems for Tuberculosis
Treatment PART V: TOWARD A TB-FREE WORLD: VACCINES, BIOMARKERS, AND THE
FUTURE
14. Advances in Tuberculosis Control: Vaccines and Biomarkers
15.
Future Perspectives and Emerging Strategies in Tuberculosis Drug Discovery
Vivek P. Chavda, MPharm, is an Assistant Professor of Pharmaceutics and Pharmaceutical Technology at the L. M. College of Pharmacy, India. He earlier served in the biologics industry in research and development with two successful regulatory filings. He has more than 250 national and international publications, nearly 20 book chapters, several books, one patent in progress as well as numerous newsletter articles to his credit. His research interests include development of biologics processes and formulations, medical device development, nano-diagnostics, long-acting parenteral formulations, and nano-vaccines.
Mahesh T. Chhabria, PhD, is a Principal and Professor at the L. M. College of Pharmacy, India. He has around 70 research publications, one patent granted, and 10 patent applications to his credit. He has availed research grants of equating to nearly $1 million USD and has also received grants for setting up of the Atal Incubation Centre at the L. M. College of Pharmacy. He has supervised around nearly 150 MPharm and PhD students. His primary field of expertise revolves around medicinal chemistry and the utilization of computer-aided drug design methodologies, focusing on innovation and advancement of novel compounds targeting tuberculosis, hyperlipidemia, cancer, and COVID-19.
Divya M. Teli, MPharm, is an Assistant Professor of Pharmaceutical Chemistry at L. M. College of Pharmacy, India. She has industrial experience of five years in the Department of Research and Development at o2h discovery Pvt. Ltd. Her area of interest includes synthesis of small organic heterocyclic molecules and indigenous novel route development for the synthesis of active pharmaceutical ingredients, key starting materials and drug intermediates, route scouting, computer aided-drug design, discovery and development of novel antitubercular, and anticancer and antiviral agents.
More information about ebooks